stoxline Quote Chart Rank Option Currency Glossary
  
Immunovant, Inc. (IMVT)
37  1.01 (2.81%)    02-23 16:00
Open: 35.94
High: 37.455
Volume: 885,219
  
Pre. Close: 35.99
Low: 35.94
Market Cap: 5,376(M)
Technical analysis
2024-02-23 4:37:28 PM
Short term     
Mid term     
Targets 6-month :  45.01 1-year :  48.33
Resists First :  38.54 Second :  41.38
Pivot price 36.48
Supports First :  33.95 Second :  28.24
MAs MA(5) :  36.82 MA(20) :  36.73
MA(100) :  37.5 MA(250) :  26.93
MACD MACD :  -0.7 Signal :  -0.8
%K %D K(14,3) :  48.5 D(3) :  52.8
RSI RSI(14): 47
52-week High :  45.58 Low :  14.05
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ IMVT ] has closed below upper band by 35.7%. Bollinger Bands are 60.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 37.51 - 37.72 37.72 - 37.91
Low: 35.39 - 35.66 35.66 - 35.91
Close: 36.6 - 37 37 - 37.37
Company Description

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Headline News

Fri, 23 Feb 2024
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares - Yahoo Finance

Fri, 23 Feb 2024
Immunovant, Inc. (NASDAQ:IMVT) Given Average Recommendation of “Buy” by Brokerages - AmericanBankingNEWS

Fri, 23 Feb 2024
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Rating of "Buy" from Analysts - MarketBeat

Tue, 20 Feb 2024
JP Morgan Initiates Coverage of Immunovant (IMVT) with Overweight Recommendation - MSN

Tue, 20 Feb 2024
Immunovant (NASDAQ:IMVT) Shares Gap Up to $37.13 - MarketBeat

Wed, 14 Feb 2024
Is Immunovant Inc (IMVT) a Good Choice in Biotechnology Wednesday? - InvestorsObserver

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 145 (M)
Shares Float 65 (M)
Held by Insiders 55.5 (%)
Held by Institutions 47.7 (%)
Shares Short 8,310 (K)
Shares Short P.Month 7,460 (K)
Stock Financials
EPS -1.81
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.67
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -27.2 %
Return on Equity (ttm) -44.6 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.75
Qtrly Earnings Growth 0 %
Operating Cash Flow -210 (M)
Levered Free Cash Flow -126 (M)
Stock Valuations
PE Ratio -20.45
PEG Ratio -5.8
Price to Book value 7.9
Price to Sales 0
Price to Cash Flow -25.56
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android